GlaxoSmithKline, which is making big investments in manufacturing in the U.K., will help its homeland try to figure out how to revive its manufacturing base.
While Finland agreed to pay out in 2011, the U.K. was still knocking back claimants in 2012. Now, though, the U.K. government is reportedly readying to pay 60 people $1.7 million each.
The United Kingdom's long history of public healthcare gives it an enviable trove of patient data. Yet this resource, which is perhaps the one true competitive edge possessed by U.K. biopharma, is at risk of being squandered as the project continues to buried by mismanagement and a blizzard of negative publicity.
Horizon Discovery Group, which makes and sells tools for genomics research and personalized medicines, has set out to raise about $41.5 million on the AIM market on the London Stock Exchange.
GlaxoSmithKline is investing £350 million in a new plant in Ulverston, U.K., that will generate 500 new jobs, increase drug capacity and potentially draw on wind power to lower its environmental impact. But what about the football fields?
Biogen Idec's hot-selling multiple sclerosis drug Tecfidera has to win reimbursement in individual European countries where governments have gotten stingy about parting with healthcare dollars. A decision Thursday by U.K. price watchdog NICE is an indication of the cost hurdles to be faced.
I've been in the U.K. for a few days now, grabbing some meetings along the way after discussing valuations in biotechnology with a group of One Nucleus members at The Babraham Institute near Cambridge. And I've been thinking about this question a lot this week.
The U.K.'s National Health Service hired a lobbying group, Specialised Healthcare Alliance (SHCA), to write a report on strategies for care, which could influence health policy, The Guardian reports.
The British government has been unveiling a series of genomics and bioinformatics initiatives intended to revive its ailing biopharma industry. This week brought news of $52 million in funding for 5 bioinformatics projects run by British research institutes.
European financial markets have largely missed out on the biotech IPO boom, with the few local companies to go public traveling to the U.S. to file their papers. Now British vaccine developer Circassia is to test investor appetite in the United Kingdom with a bumper $285 million IPO.